Document Type: Research Articles
College of Applied Medical Sciences, Qassim University, Buraidah, Al-Qassim, Saudi Arabia.
Objective: Cancer chemotherapy at the recommended doses is largely associated with toxicity, and also it is not
effective enough to reduce the advancement of the disease at lower doses. Thymoquinone (TQ) is an active compound
derived from black seeds (Nigella sativa) which exhibits anticancer activities. The aim of the present study was to
investigate the synergistic effect of TQ alone and in combination with cyclophosphamide (cyclo), and to unravel the
role of TQ in fatty acid synthase (FASN) mediated molecular signaling in Her2 + and Her2- breast cancer cell lines.
Methods: The effect of TQ on the growth of Her2+ SKBR-3 and Her2- MDA-231 breast cancer lines were evaluated
as percent cell viability by cytotoxicity-based MTT assay. The analysis of cell cycle arrest was done through flowcytometry
followed by Western blot and RT-PCR to detect signaling events in the cells. Results: The data showed
that TQ-cyclo (0.5mM-10μM) combination significantly inhibited the proliferation through the 5.49% and 57.72%
accumulation of cells in sub-G1 and G1 respectively as 12% cells were shifted from G2/M phase in Her2+ breast cancer
cells. Similarly, TQ-cyclo (0.5mM-20μM) combination exhibited that the 16.6% cells were arrested in Sub-G1 and only
3.54% cells were remained in G2/M phase as it was 22.89% in DMSO control in Her-2- breast cancers cells. Though
TQ alone or in combination with cyclo alleviated the PI3K/Akt signaling by downregulating the phosphorylation of Akt
and upregulating the PTEN, no changes was observed in FASN and Her-2 as well in both type of cells. The significant
decreased expression of cyclin D1 was found in TQ-cyclo combinations. Conclusion: The current findings suggested
that TQ can alter the cell cycle progression and induce cell death independent of FASN mediated signaling. In terms of
clinical perspective, the present study clearly showed that TQ can broadly augment the effect of cyclo in breast cancer
cases irrespective of Her-2+ or Her-.